Biocon Pharma Limited Receives U.S. FDA Approval for Liraglutide Injection gVictoza®

NOTIFICATION TO STOCK EXCHANGE

COMPANY STATEMENT

Biocon Pharma Limited, a wholly-owned subsidiary of the Company, has received approval from the U.S Food and Drug Administration (U.S. FDA) for its ANDA for Liraglutide Injection (gVictoza®), 18 mg/3 mL (6 mg/mL), Single-Patient-Use Prefilled Pens. Liraglutide is indicated for the treatment of insufficiently controlled Type 2 Diabetes Mellitus in adults, adolescents and children aged 10 years and above, as an adjunct to diet and exercise.

This follows the approval for Liraglutide injection (gSaxenda®) that was received by the Company on February 24, 2026, and will further strengthen Biocon’s portfolio of vertically integrated, complex drug products.